Chimeric antigen receptors (CARs) have shown promise in targeting malignancies, especially in liquid cancers, yet face challenges in achieving sustained effects in solid tumors and the unique environment of brain tumors.
The recent findings highlight that GD2, a disialoganglioside, is highly expressed on H3K27M-mutated diffuse midline gliomas, allowing for effective targeting and potential treatment via CAR T-cell therapy.
Despite prior approaches failing, the administration of GD2-CAR T-cells has shown encouraging preclinical results by completely eradicating DMGs in models, suggesting a new avenue for therapy.
DIPG, being the most common brain cancer in children, has grim prognoses, prompting the exploration of immuno-oncology strategies, which, though still early in development, show potential for improved outcomes.
Collection
[
|
...
]